Pharmacotherapies for Co-Occurring Stimulant Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Network Meta-Analysis.
J Clin PsychiatryAug 31, 2026 (epub)
Clinical ResearchPsychiatry
Henrique N P Oliva, Alejandra Pulido-Saavedra, Alisson M Paredes Naveda et al.
✦ AI-curated · Sources linked
In 30 seconds
This network meta-analysis evaluated pharmacotherapies for adults with co-occurring stimulant use disorder (StUD) and attention-deficit/hyperactivity disorder (ADHD). Six studies were included, revealing that higher-dose methylphenidate (MPH) and mixed amphetamine salt (MAS) significantly improved outcomes. MAS showed the greatest benefit for continuous abstinence from stimulants (OR=8.45; 95% CI, 2.55-27.98; P =.0005).
Key findings
- MAS produced the greatest benefit for continuous abstinence from stimulants (OR=8.45; 95% CI, 2.55-27.98; P =.0005).
- Pharmacotherapy increased the odds of negative urine tests (OR=1.65; 95% CI, 1.01-2.71; P =.05).
- Improvement in ADHD symptom severity was significant (SMD=-0.59; 95% CI, -0.94 to -0.23; P =.001).
- Higher doses of MPH and MAS ranked highest in treatment effectiveness.
Why it matters
The findings highlight the potential for optimized stimulant dosing in treating patients with both StUD and ADHD, which may enhance treatment outcomes and improve patient management strategies.